ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Long Non-coding RNA DLGAP1-AS1 and DLGAP1-AS2: Two Novel Oncogenes in Multiple Cancers

Zhao, Fangnan; Tan, Fangshun; Tang, Lu; Du, Zhuoying; Chen, Xiaoya; Yang, Yuzhi; Zhou, Gang*; Yuan, Chengfu*china three gorges univ
Current Medicinal Chemistry2023DOI: 10.2174/0929867329666220919114919
6阅读
引用收藏
分享

摘要

Background The change of lncRNA expression is known to affect the progression of tumors. This has fueled numerous investigations aiming at the mystery of lncRNA. Clear lncRNA has been the hotspot of antisense RNAs research. More and more lncRNAs have been proven to take effect as oncogenes of multitudinous cancers and accelerate tumor progression. This review elucidates the pathophysiological functions of lncRNA DLGAP1-AS1 and lncRNA DLGAP1-AS2 in a variety of tumors. Methods Via systematic analysis and in-depth study about relevant articles in PubMed, this article analyzes and summarizes the mechanism of antisense transcripts DLGAP1-AS1 and DLGAP1-AS2 in tumor development. Results DLGAP1-AS1 and DLGAP1-AS2 can exert their effect as oncogenes on various cancers. The expression of DLGAP1-AS1 is aberrantly high in various tumors, including GC, BC, HCC, glioblastoma and CRC. Concurrently, in LC, RC, HCC, GC, glioma and CCA, DLGAP1-AS2 is also discovered to be highly expressed. And they have a strong pertinence with a poor prognosis. The disorder of DLGAP1-AS1 and DLGAP1-AS2 in different tumors has different malignant impacts on tumors, not only to invasion, apoptosis, multiplication and EMT of tumor cells but also to drug resistance and radioresistance. In addition, DLGAP1-AS2 was revealed to have the ability to predict the prognosis of WT and RCC. Conclusion The regulatory effects of DLGAP1-AS1 and DLGAP1-AS2 on tumors make them possible to be clinical markers for the early diagnosis of tumors and effective therapeutic targets.

学科与关键词

关键词
Long non-coding RNADLGAP1-AS1DLGAP1-AS2tumorprognosisbiomarkers therapeutic target
相关
加载中…
  • AGAP2-AS1: An Indispensable lncRNA in Tumors
    Chen, Jinlan; Wang, Bei*MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23(3): 336-342.被引 1
  • Association of LncRNA PCBP1-AS1 with cancer occurrence and development: A review
    Wu, Yanping; Mou, Jie; Liu, Yuling; Zheng, Wenfei*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2023, 102(43): e35631.
  • LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer
    Hu, Chengyu*MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23(5): 530-536.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Current Medicinal Chemistry
发表日期
2023
卷期
第 30 卷, 第 25 期
页码
2822-2834
DOI
10.2174/0929867329666220919114919
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhao, Fangnan (第一作者)

    china three gorges univ

  • T

    Tan, Fangshun

    china three gorges univ

查看全部 8 位作者收起作者
  • T

    Tang, Lu

    china three gorges univ

  • D

    Du, Zhuoying

    china three gorges univ

  • C

    Chen, Xiaoya

    china three gorges univ

  • Y

    Yang, Yuzhi

    china three gorges univ

  • Z

    Zhou, Gang (通讯)

    china three gorges univ

  • Y

    Yuan, Chengfu (通讯)

    china three gorges univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417